Scilex Holding (SCLX) Submits a Request to the SEC to Withdraw its Registration Statement on Form S-1
- Wall Street ends mixed after job openings hint at cooling economy
- MongoDB delivers upbeat guidance after Q3 results beat
- U.S. job openings fall to 8.733 million in October - JOLTS report
- Hedge Funds were big sellers of Big Tech stocks last week - Morgan Stanley
- CVS Health adds 2% as 2024 revenue outlook tops estimates
Scilex Holding Company (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, submitted a request to the Securities and Exchange Commission (the “SEC”) to withdraw its Registration Statement on Form S-1 (File No. 333-271401) (the “Registration Statement”), as amended, initially filed with the SEC on April 21, 2023. The Company anticipates that, in accordance with SEC rules and regulations, such request will be deemed granted as of the date of such request, unless the SEC notifies the Company within 15 days that such request will not be granted. The Registration Statement had not been declared effective by the SEC, and no securities had been sold pursuant to the Registration Statement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credo Technology (CRDO) announces launch of public offering
- Crown Castle (CCI) Announces Proposed Offering of Senior Notes
- Vesta (VTMX) Announces Proposed Follow-On Offering
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesS1, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!